• Aminopeptidase Inhibition Alters Angiotensin Signaling in Ra

  2026-05-09

  Harding and Felix's study demonstrates that inhibiting aminopeptidase B with bestatin hydrochloride amplifies angiotensin II and III-induced neuronal responses in the rat brain. These findings clarify the enzymatic regulation of neuropeptide signaling in central angiotensin pathways, with implications for mechanistic neuroscience and translational research.

• Angiotensin 1/2 (1-6): Integrative Roles in Cardiovascular a

  2026-05-08

  Explore the multifaceted research applications of Angiotensin 1/2 (1-6), including its role in vascular tone regulation and its emerging significance in SARS-CoV-2 spike protein interactions. This article offers a unique, evidence-based perspective on the Asp-Arg-Val-Tyr-Ile-His hexapeptide for advanced renin-angiotensin system research.

• DMXAA (Vadimezan): Precision Disruption of Tumor Vasculature

  2026-05-08

  Explore how DMXAA (Vadimezan) redefines apoptosis induction and tumor vasculature disruption in cancer biology research. This article uniquely bridges vascular targeting with new STING-JAK1 immunological paradigms, offering a deeper scientific perspective for advanced assay design.

• Safe DNA Gel Stain: Protocol Optimization and Applied Use-Ca

  2026-05-07

  Safe DNA Gel Stain offers a safer, high-sensitivity alternative for DNA and RNA visualization, enabling advanced workflow flexibility and improved cloning outcomes. This article details real-world protocol enhancements, troubleshooting strategies, and experimental insights grounded in recent biomimetic and translational research.

• Inhibiting Extracellular Vesicle Release in TNBC: Calpeptin’

  2026-05-07

  McNamee et al. (2023) systematically evaluated inhibitors of extracellular vesicle (EV) release in triple-negative breast cancer (TNBC) cell lines, identifying that broad inhibition—including with Calpeptin—markedly restricts the transmission of aggressive cancer traits. Their findings clarify the contribution of EVs to cancer progression and provide a robust experimental foundation for targeting EV-mediated communication.

• Deferasirox Fe3+ Chelate: Optimizing Iron Overload Research

  2026-05-06

  Deferasirox Fe3+ chelate (Exjade) enables reproducible, high-fidelity iron overload treatment research, especially in beta-thalassemia and chronic anemia models. APExBIO’s DMSO-soluble formulation offers robust workflow compatibility and addresses key troubleshooting bottlenecks in mechanistic and phenotypic iron chelation studies.

• AT-406 (SM-406): Precision Apoptosis Induction in Cancer Res

  2026-05-06

  AT-406 (SM-406) empowers oncology researchers to precisely modulate apoptosis pathways, overcome chemoresistance, and optimize in vitro and in vivo cancer models. This guide translates bench-validated workflows, troubleshooting strategies, and the latest cross-species insights into actionable recommendations for successful experimental outcomes.

• Bestatin Hydrochloride: Neuroendocrine Precision in Angioten

  2026-05-05

  Explore how Bestatin hydrochloride (Ubenimex) uniquely enables precise modulation of neuroendocrine angiotensin signaling and aminopeptidase activity. This article delivers scientific depth and practical assay insights, distinguishing itself from current cancer-focused content.

• Captopril’s Dual Mechanisms: Bridging ACE Inhibition and GI

  2026-05-05

  This thought-leadership article explores the mechanistic intricacies and translational opportunities of Captopril, a gold-standard ACE inhibitor. By integrating cardiovascular and gastrointestinal research, it provides actionable guidance for scientists seeking to leverage Captopril’s dual role in hypertension and oncology, while bridging into bradykinin-mediated modulation of peristalsis. The article highlights evidence-based protocols, competitive insights, and a forward-looking perspective on cross-domain research.

• Preclinical Characterization of Anlotinib: Selective VEGFR2

  2026-05-04

  This article examines the preclinical study of anlotinib hydrochloride, a highly selective multi-target tyrosine kinase inhibitor with potent anti-angiogenic activity. The research demonstrates anlotinib’s superior efficacy in inhibiting VEGFR2-mediated angiogenesis and tumor growth, providing a strong foundation for its application in cancer research.

• Phosphatase Inhibitor Cocktail 1: Preserving Cardiac Signali

  2026-05-04

  Explore how Phosphatase Inhibitor Cocktail 1 ensures robust protein phosphorylation preservation in cardiovascular research. This article uniquely connects single-cell signaling insights with advanced assay strategies for heart failure models.

• Bradykinin B2 Receptors Inhibit Ileal Peristalsis: Mechanist

  2026-05-03

  This study delivers the first direct evidence that bradykinin modulates gastrointestinal motility by inhibiting the peristaltic reflex via B2 receptor activation in the guinea pig ileum. The findings clarify receptor-specific control of gut peristalsis and offer a mechanistic foundation relevant to ACE inhibition research and bradykinin pathway modulation.

• Catalpol’s Protective Roles in Cardio-Cerebrovascular Diseas

  2026-05-02

  This review comprehensively examines catalpol, an iridoid glucoside from Rehmannia glutinosa, highlighting its multi-pathway mechanisms in protecting against cardio-cerebrovascular diseases (CVDs). The article situates catalpol’s molecular actions within the context of contemporary hypertension and cardiovascular research, drawing methodologic parallels to established ACE inhibitor workflows.

• Angiotensin III: Strategic Insights for Translational Resear

  2026-05-01

  This thought-leadership article explores Angiotensin III (human, mouse) as a next-generation RAAS peptide, blending mechanistic detail with actionable guidance for cardiovascular, neuroendocrine, and emerging viral pathogenesis research. We contextualize recent mechanistic breakthroughs, validate experimental protocols, and strategically position Angiotensin III for translational innovation—bridging preclinical discovery and clinical opportunity.

• Controlled Self-Renewal and Differentiation in Human Intesti

  2026-05-01

  This study establishes a tunable human intestinal organoid system that achieves a controlled balance between stem cell self-renewal and differentiation without the need for artificial niche gradients. By leveraging small molecule pathway modulators, the system enhances both proliferative capacity and cellular diversity, opening new possibilities for high-throughput tissue modeling and disease research.

15300 records 1/1020 page Next 12345 下5页 Last page